1274 results Stibbe assisted Centerbridge Partners with the sale of FLI Group’s 8-Hotel Portfolio to Alchemy Step Hotel Group Stibbe assisted global private investment firm Centerbridge Partners with the sale of FLI Group’s 8-Hotel Portfolio to Alchemy Step Hotel Group (ASHG), an investment platform in the European hotel sector. You win some, you lose some: Google AdSense decision annulled The General Court has annulled the EUR 1.49 billion fine imposed on Google. The Commission had failed to properly assess the allegedly abusive contractual clauses related to online advertising, including whether they actually had a lock-in effect. Qualcomm falls prey to EU court’s predatory pricing ruling The EU General Court confirms that Qualcomm’s below-cost pricing strategy designed to eliminate competition was predatory. This judgment, the first of its kind in over a decade, provides useful guidance on predatory pricing practices. Get ready for more action! Dutch investment screening continues to evolve Dutch investment screening is rapidly expanding: since June, the proposal for a separate defence regime has been published and the intended expansion of the regime of the Vifo Act to include AI and biotech has been announced. Reason for a quick update! Mira Deweerdt Junior Associate Brussels Google Shopping: self-preferencing can be abusive The European Court of Justice has confirmed that Google abused its dominance by favouring its own shopping comparison service and demoting competing ones. However, not all favouritism is doomed. Alexandra Dear Senior Associate Luxembourg Sterre Thijssen Junior Associate Amsterdam Court of Appeal overturns first instance judgment and establishes that several prestressing steel producers are liable for the potential loss alleged by Deutsche Bahn The Court of Appeal of 's-Hertogenbosch ruled that several producers of prestressing steel are jointly and severally liable for potential loss that Deutsche Bahn may have suffered as a result of an infringement of competition law rules. AFM review indicates lack of transparency in use of alternative performance measures by Dutch issuers AFM sets out the findings of its review of the use of alternative performance measures in financial reporting and concludes that Dutch issuers often fall short of the required level of transparency when reporting their alternative performance measures. District Court ruled on the recognition of the res judicata effect of a Turkish judgment and dismissed an antitrust follow on damages claim regarding the cathode-ray tube markets The District Court of Oost-Brabant recognized the res judicata effect of a Turkish court of appeal judgment, in which the Turkish court had dismissed antitrust damages claims brought by Vestel against Philips, Samsung, LGE, Technicolor, TTD and TDP. Stibbe advises Palex Medical Stibbe is advising Palex Medical, a Spain-based company specialising in high value-added MedTech equipment and solutions, on its planned acquisition of Duomed, a fast-growing European MedTech distributor. Egbert Vroom Partner Amsterdam Stibbe assists Atairos Stibbe assisted Atairos regarding the Luxembourg legal aspects of its investment to become a minority partner in V Sports S.C.S., a Luxembourg holding company being the current owner of Aston Villa Football Club. Stibbe assists Rhône with its partnership with Orkla Stibbe assisted investment vehicles affiliated with Rhône Capital on a partnership with Orkla whereby Rhône acquired 40% of the shares in Orkla Food Ingredients (OFI). Stibbe advises GRW on the acquisition of Van Hool’s industrial vehicle division Stibbe advised GRW, the South African tanker and trailer manufacturer allied with Schmitz Cargobull, on acquiring the industrial vehicle division of Van Hool, following the latter’s declaration of bankruptcy. Stibbe advises Goed A multidisciplinary Stibbe team advised Goed and its shareholders on its binding agreement with Mulitpharma relating to the sale of Goed’s pharmaceutical retail and wholesale business. The Commission’s ‘killer’ pharma campaign: reason to complain? The European Commission is on the prowl in the pharma sector. Recent cases on alleged disparagement and pipeline drugs-killings show that it is not afraid to show its teeth and, ultimately, bite. Pagination Previous page Page 22 Current page 23 Page 24 Page 25 Next page
Stibbe assisted Centerbridge Partners with the sale of FLI Group’s 8-Hotel Portfolio to Alchemy Step Hotel Group Stibbe assisted global private investment firm Centerbridge Partners with the sale of FLI Group’s 8-Hotel Portfolio to Alchemy Step Hotel Group (ASHG), an investment platform in the European hotel sector.
You win some, you lose some: Google AdSense decision annulled The General Court has annulled the EUR 1.49 billion fine imposed on Google. The Commission had failed to properly assess the allegedly abusive contractual clauses related to online advertising, including whether they actually had a lock-in effect.
Qualcomm falls prey to EU court’s predatory pricing ruling The EU General Court confirms that Qualcomm’s below-cost pricing strategy designed to eliminate competition was predatory. This judgment, the first of its kind in over a decade, provides useful guidance on predatory pricing practices.
Get ready for more action! Dutch investment screening continues to evolve Dutch investment screening is rapidly expanding: since June, the proposal for a separate defence regime has been published and the intended expansion of the regime of the Vifo Act to include AI and biotech has been announced. Reason for a quick update!
Google Shopping: self-preferencing can be abusive The European Court of Justice has confirmed that Google abused its dominance by favouring its own shopping comparison service and demoting competing ones. However, not all favouritism is doomed.
Court of Appeal overturns first instance judgment and establishes that several prestressing steel producers are liable for the potential loss alleged by Deutsche Bahn The Court of Appeal of 's-Hertogenbosch ruled that several producers of prestressing steel are jointly and severally liable for potential loss that Deutsche Bahn may have suffered as a result of an infringement of competition law rules.
AFM review indicates lack of transparency in use of alternative performance measures by Dutch issuers AFM sets out the findings of its review of the use of alternative performance measures in financial reporting and concludes that Dutch issuers often fall short of the required level of transparency when reporting their alternative performance measures.
District Court ruled on the recognition of the res judicata effect of a Turkish judgment and dismissed an antitrust follow on damages claim regarding the cathode-ray tube markets The District Court of Oost-Brabant recognized the res judicata effect of a Turkish court of appeal judgment, in which the Turkish court had dismissed antitrust damages claims brought by Vestel against Philips, Samsung, LGE, Technicolor, TTD and TDP.
Stibbe advises Palex Medical Stibbe is advising Palex Medical, a Spain-based company specialising in high value-added MedTech equipment and solutions, on its planned acquisition of Duomed, a fast-growing European MedTech distributor.
Stibbe assists Atairos Stibbe assisted Atairos regarding the Luxembourg legal aspects of its investment to become a minority partner in V Sports S.C.S., a Luxembourg holding company being the current owner of Aston Villa Football Club.
Stibbe assists Rhône with its partnership with Orkla Stibbe assisted investment vehicles affiliated with Rhône Capital on a partnership with Orkla whereby Rhône acquired 40% of the shares in Orkla Food Ingredients (OFI).
Stibbe advises GRW on the acquisition of Van Hool’s industrial vehicle division Stibbe advised GRW, the South African tanker and trailer manufacturer allied with Schmitz Cargobull, on acquiring the industrial vehicle division of Van Hool, following the latter’s declaration of bankruptcy.
Stibbe advises Goed A multidisciplinary Stibbe team advised Goed and its shareholders on its binding agreement with Mulitpharma relating to the sale of Goed’s pharmaceutical retail and wholesale business.
The Commission’s ‘killer’ pharma campaign: reason to complain? The European Commission is on the prowl in the pharma sector. Recent cases on alleged disparagement and pipeline drugs-killings show that it is not afraid to show its teeth and, ultimately, bite.